← All publications

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2

Raig ND, Surridge KJ, Sanz-Murillo M, … Knapp S · Sci Adv 2025 · Sci Adv 11(23):eadt2050

LRRK2 Ser/Thr kinase Inhibitor discovery & SARMechanism & structural biology PhosphoSens

Read the paper View on PubMed

More publications on LRRK2

Novel LRR-ROC Motif That Links the N- and C-terminal Domains in LRRK2 Undergoes an Order-Disorder Transition Upon Activation

Weng JH, Trilling CR, Kaila Sharma P, … Taylor SS · J Mol Biol 2023

Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?

Tsitokana ME, Lafon PA, Prézeau L, … Rondard P · Int J Mol Sci 2023

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

Singh RK, Soliman A, Guaitoli G, … Versées W · Proc Natl Acad Sci U S A 2022

A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity

Silva RG, Geoghegan KF, Qiu X, Aulabaugh A · Anal Biochem 2014

Design, synthesis, and evaluation of a selective chemosensor for leucine-rich repeat kinase 2

Szalewski DA, Beck JR, Stains CI · Bioorg Med Chem Lett 2014

AssayQuant Technologies logo

 

 

260 Cedar Hill Street
Marlboro MA 01752

Phone: +1 (508) 804-3155

      

© 2026 AssayQuant Technologies, Inc. - All Rights Reserved - Privacy Policy - Terms & Conditions - FCOI